FINEARTS-HF Analysis: How Liver Biomarkers Influence Heart Failure Risk
Semaglutide and Cardiovascular Risk Reduction: What the Latest Data Tell Us
ACC 2025: Intravenous Iron Safe, but Results in Mixed Findings for Patients With Heart Failure
ACC 2025: Oral Semaglutide Reduces Cardiovascular Events by 14% at 4 Years